The regulatory consultancy NDA Group has appointed Robert Kronqvist as general manager for its Nordic affiliate headquartered in Stockholm, to help biotech companies bring their products through registration and onto the market. Mr Kronqvist was most recently director of analytical development and quality control at the Research Institutes of Sweden, a network of public research and technology organisations. Earlier, he spent 15 years at AstraZeneca Plc in increasing positions of responsibility, ending as head of the company’s neuroscience department in Sweden. Following the closure of the AstraZeneca site in Södertälje, Mr Kronqvist moved to BioChromix AB, a neuroscience company, as chief executive.
NDA Group announced the appointment on 20 August 2019.
Copyright 2019 Evernow Publishing Ltd.